BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 32860983)

  • 1. Detoxification of toxin A and toxin B by copper ion-catalyzed oxidation in production of a toxoid-based vaccine against Clostridioides difficile.
    Aminzadeh A; Tiwari MK; Mamah Mustapha SS; Navarrete SJ; Henriksen AB; Møller IM; Krogfelt KA; Bjerrum MJ; Jørgensen R
    Free Radic Biol Med; 2020 Nov; 160():433-446. PubMed ID: 32860983
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity and safety in rabbits of a Clostridioides difficile vaccine combining novel toxoids and a novel adjuvant.
    Aminzadeh A; Hilgers L; Paul Platenburg P; Riou M; Perrot N; Rossignol C; Cauty A; Barc C; Jørgensen R
    Vaccine; 2024 Mar; 42(7):1582-1592. PubMed ID: 38336558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a recombinant toxin fragment vaccine for Clostridium difficile infection.
    Karczewski J; Zorman J; Wang S; Miezeiewski M; Xie J; Soring K; Petrescu I; Rogers I; Thiriot DS; Cook JC; Chamberlin M; Xoconostle RF; Nahas DD; Joyce JG; Bodmer JL; Heinrichs JH; Secore S
    Vaccine; 2014 May; 32(24):2812-8. PubMed ID: 24662701
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nanobodies against C. difficile TcdA and TcdB reveal unexpected neutralizing epitopes and provide a toolkit for toxin quantitation in vivo.
    Kordus SL; Kroh HK; Rodríguez RC; Shrem RA; Peritore-Galve FC; Shupe JA; Wadzinski BE; Lacy DB; Spiller BW
    PLoS Pathog; 2023 Oct; 19(10):e1011496. PubMed ID: 37871122
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel approach to generate a recombinant toxoid vaccine against Clostridium difficile.
    Donald RGK; Flint M; Kalyan N; Johnson E; Witko SE; Kotash C; Zhao P; Megati S; Yurgelonis I; Lee PK; Matsuka YV; Severina E; Deatly A; Sidhu M; Jansen KU; Minton NP; Anderson AS
    Microbiology (Reading); 2013 Jul; 159(Pt 7):1254-1266. PubMed ID: 23629868
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systematic Evaluation of Parameters Important for Production of Native Toxin A and Toxin B from
    Aminzadeh A; Jørgensen R
    Toxins (Basel); 2021 Mar; 13(4):. PubMed ID: 33801738
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Defining the Roles of TcdA and TcdB in Localized Gastrointestinal Disease, Systemic Organ Damage, and the Host Response during Clostridium difficile Infections.
    Carter GP; Chakravorty A; Pham Nguyen TA; Mileto S; Schreiber F; Li L; Howarth P; Clare S; Cunningham B; Sambol SP; Cheknis A; Figueroa I; Johnson S; Gerding D; Rood JI; Dougan G; Lawley TD; Lyras D
    mBio; 2015 Jun; 6(3):e00551. PubMed ID: 26037121
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of an Effective Nontoxigenic Clostridioides difficile-Based Oral Vaccine against C. difficile Infection.
    Wang S; Zhu D; Sun X
    Microbiol Spectr; 2022 Jun; 10(3):e0026322. PubMed ID: 35583336
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intrarectal instillation of Clostridium difficile toxin A triggers colonic inflammation and tissue damage: development of a novel and efficient mouse model of Clostridium difficile toxin exposure.
    Hirota SA; Iablokov V; Tulk SE; Schenck LP; Becker H; Nguyen J; Al Bashir S; Dingle TC; Laing A; Liu J; Li Y; Bolstad J; Mulvey GL; Armstrong GD; MacNaughton WK; Muruve DA; MacDonald JA; Beck PL
    Infect Immun; 2012 Dec; 80(12):4474-84. PubMed ID: 23045481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clostridium difficile chimeric toxin receptor binding domain vaccine induced protection against different strains in active and passive challenge models.
    Tian JH; Glenn G; Flyer D; Zhou B; Liu Y; Sullivan E; Wu H; Cummings JF; Elllingsworth L; Smith G
    Vaccine; 2017 Jul; 35(33):4079-4087. PubMed ID: 28669616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genomic and Phenotypic Characterization of the Nontoxigenic Clostridioides difficile Strain CCUG37785 and Demonstration of Its Therapeutic Potential for the Prevention of C. difficile Infection.
    Wang S; Heuler J; Wickramage I; Sun X
    Microbiol Spectr; 2022 Apr; 10(2):e0178821. PubMed ID: 35315695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neutralizing epitopes on
    Chen B; Perry K; Jin R
    Front Immunol; 2022; 13():978858. PubMed ID: 36466927
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development and characterization of phage display-derived anti-toxin antibodies neutralizing TcdA and TcdB of
    Raeisi H; Azimirad M; Asadzadeh Aghdaei H; Zarnani AH; Abdolalizadeh J; Yadegar A; Zali MR
    Microbiol Spectr; 2023 Sep; 11(5):e0531022. PubMed ID: 37668373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low Density Lipoprotein Receptor-Related Protein-1 (LRP1) Is Involved in the Uptake of
    Schöttelndreier D; Langejürgen A; Lindner R; Genth H
    Front Cell Infect Microbiol; 2020; 10():565465. PubMed ID: 33194803
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Streamlined Method to Obtain Biologically Active TcdA and TcdB Toxins from
    Sapa D; Brosse A; Coullon H; Péan de Ponfilly G; Candela T; Le Monnier A
    Toxins (Basel); 2024 Jan; 16(1):. PubMed ID: 38251254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An Update on
    Martínez-Meléndez A; Cruz-López F; Morfin-Otero R; Maldonado-Garza HJ; Garza-González E
    Toxins (Basel); 2022 Apr; 14(5):. PubMed ID: 35622552
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic antibody responses induced by a two-component Clostridium difficile toxoid vaccine protect against C. difficile-associated disease in hamsters.
    Anosova NG; Brown AM; Li L; Liu N; Cole LE; Zhang J; Mehta H; Kleanthous H
    J Med Microbiol; 2013 Sep; 62(Pt 9):1394-1404. PubMed ID: 23518659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A chimeric toxin vaccine protects against primary and recurrent Clostridium difficile infection.
    Wang H; Sun X; Zhang Y; Li S; Chen K; Shi L; Nie W; Kumar R; Tzipori S; Wang J; Savidge T; Feng H
    Infect Immun; 2012 Aug; 80(8):2678-88. PubMed ID: 22615245
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human α-Defensin-6 Neutralizes
    Barthold L; Heber S; Schmidt CQ; Gradl M; Weidinger G; Barth H; Fischer S
    Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35562899
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Murine Intrarectal Instillation of Purified Recombinant
    Markham NO; Bloch SC; Shupe JA; Laubacher EN; Thomas AK; Kroh HK; Childress KO; Peritore-Galve FC; Washington MK; Coffey RJ; Lacy DB
    Infect Immun; 2021 Mar; 89(4):. PubMed ID: 33468584
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.